Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer

Prabhakar Pitta Venkata, Sridharan Jayamohan, Yi He, Salvador Alejo, Jessica D. Johnson, Bridgitte E. Palacios, Uday P. Pratap, Yihong Chen, Zexuan Liu, Yi Zou, Zhao Lai, Takayoshi Suzuki, Suryavathi Viswanadhapalli, Susan T. Weintraub, Srinath Palakurthi, Philip T. Valente, Rajeshwar R. Tekmal, Edward R. Kost, Ratna K. Vadlamudi, Gangadhara R. Sareddy

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Ovarian cancer (OCa) is the most lethal gynecologic cancer. Emerging data indicates that estrogen receptor beta (ERβ) functions as a tumor suppressor in OCa. Lysine-specific histone demethylase 1A (KDM1A) is an epigenetic modifier that acts as a coregulator for steroid hormone receptors. However, it remain unknown if KDM1A interacts with ERβ and regulates its expression/functions in OCa. Analysis of TCGA data sets indicated KDM1A and ERβ expression showed an inverse relationship in OCa. Knockout (KO), knockdown (KD), or inhibition of KDM1A increased ERβ isoform 1 expression in established and patient-derived OCa cells. Further, KDM1A interacts with and functions as a corepressor of ERβ, and its inhibition enhances ERβ target gene expression via alterations of histone methylation marks at their promoters. Importantly, KDM1A-KO or -KD enhanced the efficacy of ERβ agonist LY500307, and the combination of KDM1A inhibitor (KDM1Ai) NCD38 with ERβ agonist synergistically reduced the cell viability, colony formation, and invasion of OCa cells. RNA-seq and DIA mass spectrometry analyses showed that KDM1A-KO resulted in enhanced ERβ signaling and that genes altered by KDM1A-KO and ERβ agonist were related to apoptosis, cell cycle, and EMT. Moreover, combination treatment significantly reduced the tumor growth in OCa orthotopic, syngeneic, and patient-derived xenograft models and proliferation in patient-derived explant models. Our results demonstrate that KDM1A regulates ERβ expression/functions, and its inhibition improves ERβ mediated tumor suppression. Overall, our findings suggest that KDM1Ai and ERβ agonist combination therapy is a promising strategy for OCa.

Original languageEnglish (US)
Article number216383
JournalCancer Letters
Volume575
DOIs
StatePublished - Oct 28 2023

Keywords

  • Combination therapy
  • Estrogen receptor beta
  • KDM1A
  • LSD1
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer'. Together they form a unique fingerprint.

Cite this